Traduction de «based on scientific » (Néerlandais → Français) :

TERMINOLOGIE

overige stoornissen van vocht-, elektrolyten- en zuur-base-evenwicht
Autres déséquilibres hydro-électrolytiques et acido-basiques

abnormale foetale | acidemie | abnormale foetale | zuur-base-evenwicht
Acidémie | Anomalie de l'équilibre acido-basique | fœtale

gemengde stoornis van zuur-base-evenwicht
Anomalie mixte de l'équilibre acido-basique

base | stof die zout vormt
1) base - 2) base | 1) partie inférieure d'un organe - 2) base | alcalin

TRADUCTIONS EN CONTEXTE

This advisory report is largely based on expert reports and advisory reports made by the authorities competent for public health, which are themselves based on scientific articles from the international literature and reports of experimental studies.
Le présent avis est basé en grande partie sur des rapports d’expertise et des avis d’autorités de Santé publique, eux-mêmes basés sur la consultation d’articles scientifiques tirés de la littérature internationale et de rapports d’études expérimentales.

1 Based on the definitions of the Scientific Committee on Food (SCF, 1999).
1 Définition reprise du Scientific Committee on Food (SCF, 1999).

Omnitrope, the pioneering biosimilar of the recombinant human growth hormone somatropin, has received regulatory approval as the first-ever biosimilar in Japan under the brand name Somatropin BS S.C. This approval paves the way for greater access to high-quality biopharmaceuticals in the world’s second-largest pharmaceuticals market and comes about three months after Japanese authorities published guidelines for a biosimilar regulatory pathway, which is based on similar scientific principles already in place in the European Union.
Omnitrope, biosimilaire pionnier de la somatropine, une hormone de croissance humaine recombinante, a obtenu une autorisation au Japon sous la marque Somatropin BS S.C. Il s’agit du premier biosimilaire à avoir été homologué dans ce pays.

FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute).
folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRx’s pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinson’s, and Huntington’s disease based on its broad, proprietary, yeast-based drug discovery platform.

As regards the issue of authorising the use of a caffeine content of 320 mg/litre, the Council delivered an unfavourable advisory report based on two scientific expert assessments. Here it was argued that neither the nutritional significance of high caffeine doses nor the beneficial energy-boosting effects of taurine had been demonstrated.
La demande qui portait sur l’autorisation d’utiliser la caféine a raison d’une teneur de 320 mg/litre a reçu, après deux expertises scientifiques, un avis défavorable du Conseil qui signale que l’intérêt nutritionnel de doses élevées de caféine n’est pas démontré de même que les effets énergétiques favorables de la taurine.

It is also based on recent articles from the international scientific literature with the help of databases for bibliographic research.
Il se base également sur des articles récents, repris de la littérature scientifique internationale, par le biais de banques de recherche bibliographique.